Predictive value of individual serum neurofilament light chain levels in short-term disease activity in relapsing multiple sclerosis

被引:3
|
作者
Solis-Tarazona, Luis [1 ]
Raket, Lars Lau [2 ]
Cabello-Murgui, Javier [1 ]
Reddam, Salma [1 ]
Navarro-Quevedo, Silvia [3 ]
Gil-Perotin, Sara [1 ,4 ,5 ]
机构
[1] Inst Invest Sanitaria La Fe, Res Grp Immunotherapy & Biomodels Autoimmun, Valencia, Spain
[2] Lund Univ, Dept Clin Sci, Clin Memory Res Unit, Lund, Sweden
[3] Hosp Univ & Politecn La Fe, Neurol, Valencia, Spain
[4] Hosp Univ & Politecn La Fe, Multiple Sclerosis Unit, Neurol, Valencia, Spain
[5] Inst Salud Carlos III, Consorcio Ctr Invest Biomed Red CIBER, CB06-05-1131, Madrid, Spain
来源
FRONTIERS IN NEUROLOGY | 2024年 / 15卷
关键词
multiple sclerosis; biomarker; relapse; Z-score; RMS; CEREBROSPINAL-FLUID; DISABILITY;
D O I
10.3389/fneur.2024.1354431
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background The assessment of serum neurofilament light chain (sNFL) has emerged as a diagnostic and prognostic tool in monitoring multiple sclerosis (MS). However, the application of periodic measurement in daily practice remains unclear.Objective To evaluate the predictive value of individual sNFL levels in determining disease activity in patients with relapsing MS (RMS).Methods In this two-year prospective study, 129 RMS patients underwent quarterly sNFL assessments and annual MRI scans. The study analyzed the correlation between individual NFL levels and past, current, and future disease activity. Group-level Z-scores were employed as a comparative measure.Results Among the 37 participants, a total of 61 episodes of disease activity were observed. sNFL levels proved valuable in distinct ways; they were confirmatory of previous and current clinical and/or radiological activity and demonstrated a high negative predictive value for future 90 days activity. Interestingly, Z-scores marginally outperformed sNFL levels in terms of predictive accuracy, indicating the potential for alternative approaches in disease activity assessment. In our cohort, sNFL cut-offs of 10.8 pg./mL (sensitivity 27%, specificity 90%) and 14.3 pg./mL (sensitivity 15%, specificity 95%) correctly identified 7 and 4 out of 26 cases of radiological activity within 90 days, respectively, with 14 and 15% false negatives. When using lower cut-off values, individuals with sNFL levels below 5 pg/mL (with a sensitivity of 92%, specificity of 25%, and negative predictive value of 94%) were less likely to experience radiological activity within the next 3 months.Conclusion Individual sNFL levels may potentially confirm prior or current disease activity and predict short-term future radiological activity in RMS. These findings underscore its periodic measurement as a valuable tool in RMS management and decision-making, enhancing the precision of clinical evaluation in routine practice.
引用
收藏
页数:8
相关论文
共 50 条
  • [21] Serum Neurofilament Light Trajectories and Their Relation to Subclinical Radiological Disease Activity in Relapsing Multiple Sclerosis Patients in the APLIOS Trial
    Bar-Or, Amit
    Montalban, Xavier
    Hu, Xixi
    Kropshofer, Harald
    Kukkaro, Petra
    Coello, Neva
    Ludwig, Inga
    Willi, Roman
    Zalesak, Martin
    Ramanathan, Krishnan
    Kieseier, Bernd C.
    Haring, Dieter A.
    Bagger, Morten
    Fox, Edward
    NEUROLOGY AND THERAPY, 2023, 12 (01) : 303 - 317
  • [22] Association of Serum Neurofilament Light Levels With Long-term Brain Atrophy in Patients With a First Multiple Sclerosis Episode
    Plavina, Tatiana
    Singh, Carol M.
    Sangurdekar, Dipen
    de Moor, Carl
    Engle, Bob
    Gafson, Arie
    Goyal, Jaya
    Fisher, Elizabeth
    Szak, Suzanne
    Kinkel, Revere P.
    Sandrock, Alfred W.
    Su, Ray
    Kieseier, Bernd C.
    Rudick, Richard A.
    JAMA NETWORK OPEN, 2020, 3 (11)
  • [23] Monitoring disease activity in multiple sclerosis using serum neurofilament light protein
    Novakova, Lenka
    Zetterberg, Henrik
    Sundstrom, Peter
    Axelsson, Markus
    Khademi, Mohsen
    Gunnarsson, Martin
    Malmestrom, Clas
    Svenningsson, Anders
    Olsson, Tomas
    Piehl, Fredrik
    Blennow, Kaj
    Lycke, Jan
    NEUROLOGY, 2017, 89 (22) : 2230 - 2237
  • [24] Cerebrospinal fluid neurofilament light chains predicts early disease-activity in Multiple Sclerosis
    Toscano, Simona
    Oteri, Vittorio
    Chisari, Clara Grazia
    Finocchiaro, Chiara
    Lo Fermo, Salvatore
    Valentino, Paola
    Bertolotto, Antonio
    Zappia, Mario
    Patti, Francesco
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2023, 80
  • [25] Serum phosphorylated neurofilament-heavy chain levels in multiple sclerosis patients
    Gresle, M. M.
    Liu, Y.
    Dagley, L. F.
    Haartsen, J.
    Pearson, F.
    Purcell, A. W.
    Laverick, L.
    Petzold, A.
    Lucas, R. M.
    Van der Walt, A.
    Prime, H.
    Morris, D. R.
    Taylor, B. V.
    Shaw, G.
    Butzkueven, H.
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2014, 85 (11): : 1209 - 1213
  • [26] Association Between Serum Neurofilament Light Chain Levels and Long-term Disease Course Among Patients With Multiple Sclerosis Followed up for 12 Years
    Canto, Ester
    Barro, Christian
    Zhao, Chao
    Caillier, Stacy J.
    Michalak, Zuzanna
    Bove, Riley
    Tomic, Davorka
    Santaniello, Adam
    Haering, Dieter A.
    Hollenbach, Jill
    Henry, Roland G.
    Cree, Bruce A. C.
    Kappos, Ludwig
    Leppert, David
    Hauser, Stephen L.
    Benkert, Pascal
    Oksenberg, Jorge R.
    Kuhle, Jens
    JAMA NEUROLOGY, 2019, 76 (11) : 1359 - 1366
  • [27] Kappa free light chain and neurofilament light independently predict early multiple sclerosis disease activity-a cohort study
    Hegen, Harald
    Berek, Klaus
    Bsteh, Gabriel
    Auer, Michael
    Altmann, Patrick
    Di Pauli, Franziska
    Grams, Astrid
    Milosavljevic, Dejan
    Ponleitner, Markus
    Poskaite, Paulina
    Schnabl, Christine
    Wurth, Sebastian
    Zinganell, Anne
    Berger, Thomas
    Walde, Janette
    Deisenhammer, Florian
    EBIOMEDICINE, 2023, 91 : 1 - 9
  • [28] Serum neurofilament light chain in relapsing-remitting MS Unchaining disease activity prediction?
    Marrie, Ruth Ann
    NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION, 2018, 5 (01):
  • [29] Serum neurofilament light-chain levels and long-term treatment outcomes in relapsing-remitting multiple sclerosis patients: A post hoc analysis of the randomized CombiRx trial
    Cutter, Gary
    Rudick, Richard A.
    de Moor, Carl
    Singh, Carol M.
    Fisher, Elizabeth
    Koster, Thijs
    Lublin, Fred D.
    Wolinsky, Jerry S.
    McFarland, Henry
    Jacobson, Steven
    Naylor, Maria L.
    MULTIPLE SCLEROSIS JOURNAL-EXPERIMENTAL TRANSLATIONAL AND CLINICAL, 2023, 9 (02)
  • [30] Serum neurofilament light chain is a biomarker of acute and chronic neuronal damage in early multiple sclerosis
    Siller, Nelly
    Kuhle, Jens
    Muthuraman, Muthuraman
    Barro, Christian
    Uphaus, Timo
    Groppa, Sergiu
    Kappos, Ludwig
    Zipp, Frauke
    Bittner, Stefan
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 (05) : 678 - 686